Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
出版年份 2021 全文链接
标题
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
作者
关键词
-
出版物
Dermatology and Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-02
DOI
10.1007/s13555-021-00596-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
- (2021) A. Armstrong et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Emerging systemic drugs in the treatment of plaque psoriasis
- (2020) Esther A. Balogh et al. EXPERT OPINION ON EMERGING DRUGS
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
- (2019) Rujia Xie et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
- (2019) Mohamed‐Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- (2019) Michael D. Howell et al. Frontiers in Immunology
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
- (2018) Michael P. Schön et al. Frontiers in Immunology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started